Skip to search formSkip to main contentSkip to account menu

CDK4/6 Inhibitor G1T28

Known as: G1T28 
A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), with potential antineoplastic and chemoprotective activities… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Follicular Lymphoma Response with CDK4/6 Inhibitor(Palbociclib) Utilized in the Setting of Metastatic Breast Cancer
2017
2017
P2.03a-048 The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth: Topic: Clinical Trials
2016
2016
The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells.
e20099Background: Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by loss of the tumor… 
2015
2015
Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies
G1T28-1 is a clinical stage, small molecule inhibitor of cyclin dependent kinases 4/6 (CDK4/6). Hematopoietic stem and progenitor… 
2015
2015
Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy
2014
2014
Abstract LB-136: Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA The de-regulation of the Retinoblastoma tumor suppressor… 
2013
2013
Cdk4/6 억제제 및 b-raf 억제제의 제약 조합물
(a) CDK4/6 억제제, (b) B-Raf 억제제, 및 임의로 (c) MEK 1/2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)